The effects of ketamine and risperidone on eye movement control in healthy volunteers

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Schmechtig, A ^a   Lees, J ^b   Perkins, A ^a   Altavilla, A ^c   Craig, K J ^d   Dawson, G R ^d   William Deakin, J F ^b   Dourish, C T ^d   Evans, L H ^c   Koychev, I ^b   Weaver, K ^a   Smallman, R ^b   Walters, J ^e   Wilkinson, L S ^c,e   Morris, R ^a   Williams, S C R ^a   Ettinger, U ^f  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF BONN   (Germany)

Author keywords

glutamate; ketamine; risperidone; saccades; schizophrenia; smooth pursuit

Indexed keywords

KETAMINE; PLACEBO; RISPERIDONE; AMINO ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EYE MOVEMENT CONTROL; EYE MOVEMENT DISORDER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCULOMOTOR SYSTEM; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SMOOTH PURSUIT EYE MOVEMENT; VELOCITY; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; EYE MOVEMENT; NORMAL HUMAN; OCULOGRAPHY; SACCADIC EYE MOVEMENT; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; EYE MOVEMENT MEASUREMENTS; EYE MOVEMENTS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; KETAMINE; MALE; OCULAR MOTILITY DISORDERS; PURSUIT, SMOOTH; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE; SACCADES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84890625624     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.109     Document Type: Article

References (141)

1. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006; 67: e12.
2. Stone JM. Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? Ther Adv Psychopharmacol 2011; 1: 5-18.
3. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 2002; 7: 837-844.
4. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214. (Pubitemid 24081509)
5. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003; 169: 215-233. (Pubitemid 37264943)
6. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 1998; 43: 811-816. (Pubitemid 28288379)
7. Lofwall MR, Griffiths RR, Mintzer MZ. Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults. Exp Clin Psychopharmacol 2006; 14 (4): 439-449. (Pubitemid 44789965)
8. Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D'Souza DC et al. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry 2000; 47: 137-143. (Pubitemid 30069737)
9. Koychev I, Barkus E, Ettinger U, Killcross S, Roiser JP, Wilkinson L et al. Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia. J Psychopharmacol 2011; 25: 1207-1225.
10. Reilly JL, Lencer R, Bishop JR, Keedy S, Sweeney JA. Pharmacological treatment effects on eye movement control, Brain Cogn, 2008, 68, 415-435.
11. de Visser SJ, van der Post J, Pieters MS, Cohen AF, van Gerven JM. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 2001; 51: 119-132. (Pubitemid 32219735)
12. Ettinger U, Picchioni M, Hall MH, Schulze K, Toulopoulou T, Landau S et al. Antisaccade performance in monozygotic twins discordant for schizophrenia: the Maudsley twin study. American Journal of Psychiatry 2006; 163: 543-545. (Pubitemid 44469403)
13. Hutton SB, Ettinger U. The antisaccade task as a research tool in psychopathology: a critical review. Psychophysiology 2006; 43: 302-213.
14. Levy DL, Sereno AB, Gooding DC, O'Driscoll GA. Eye tracking dysfunction in schizophrenia: characterization and pathophysiology. Curr Top Behav Neurosci 2010; 4: 311-347.
15. Smyrnis N, Evdokimidis I, Mantas A, Kattoulas E, Stefanis NC, Constantinidis TS et al. Smooth pursuit eye movements in 1,087 men: effects of schizotypy, anxiety, and depression. Exp Brain Res 2007; 179: 397-408. (Pubitemid 46716593)
16. Smyrnis N, Evdokimidis I, Stefanis NC, Avramopoulos D, Constantinidis TS, Stavropoulos A et al. Antisaccade performance of 1,273 men: effects of schizotypy, anxiety, and depression. J Abnorm Psychol 2003; 112: 403-414. (Pubitemid 36959366)
17. Hutton SB. Cognitive control of saccadic eye movements. Brain Cogn 2008; 68: 327-340.
18. Barnes GR. Cognitive processes involved in smooth pursuit eye movements. Brain Cogn 2008; 68: 309-326.
19. Sharpe JA. Neurophysiology and neuroanatomy of smooth pursuit: lesion studies. Brain Cogn 2008; 68: 241-254.
20. Avila MT, Weiler MA, Lahti AC, Tamminga CA, Thaker GK. Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am J Psychiatry 2002; 159: 1490-1496. (Pubitemid 35006728)
21. Condy C, Wattiez N, Rivaud-Pechoux S, Gaymard B. Ketamine-induced distractibility: An oculomotor study in monkeys. Biol Psychiatry 2005; 57: 366-372. (Pubitemid 40215766)
22. Radant AD, Bowdle TA, Cowley DS, Kharasch ED, Roy-Byrne (Pubitemid 28451599)
23. Weiler MA, Thaker GK, Lahti AC, Tamminga CA. Ketamine effects on eye movements. Neuropsychopharmacology 2000; 23: 645-653.
24. Morgan CJ, Huddy V, Lipton M, Curran HV, Joyce EM. Is persistent ketamine use a valid model of the cognitive and oculomotor deficits in schizophrenia? Biol Psychiatry 2009; 65: 1099-1102.
25. Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 2011; 213: 289-305.
26. Large (Pubitemid 46934046)
27. Doyle OM, De Simoni S, Schwarz AJ, Brittain C, O'Daly OG, Williams SC et al. Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents. J Pharmacol Exp Ther 2013; 345: 151-160.
28. Burke JG, Reveley MA. Improved antisaccade performance with risperidone in schizophrenia. J Neurol Neurosurg Psychiatry 2002; 72: 449-454.
29. Harris MS, Reilly JL, Keshavan MS, Sweeney JA. Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia. Psychol Med 2006; 36: 485-494.
30. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 1991; 17: 555-564.
31. O'Driscoll GA, Lenzenweger MF, Holzman PS. Antisaccades and smooth pursuit eye tracking and schizotypy. Arch Gen Psychiatry 1998; 55: 837-843. (Pubitemid 28413047)
32. Ettinger U, Kumari V, Crawford TJ, Flak V, Sharma T, Davis RE et al. Saccadic eye movements, schizotypy, and the role of neuroticism. Biol Psychol 2005; 68: 61-78. (Pubitemid 39092932)
33. Schmechtig A, Lees J, Grayson L, Craig KJ, Dadhiwala R, Dawson GR et al. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. Psychopharmacology (Berl) 2013; 227: 331-345.
34. Nelson HE. The National Adult Reading Test (NART). NFER-Nelson: Windsor UK, 1982.
35. Ettinger U, Kumari V, Zachariah E, Galea A, Crawford TJ, Corr PJ et al. Effects of procyclidine on eye movements in schizophrenia. Neuropsychopharmacology 2003; 28: 2199-2208. (Pubitemid 37468188)
36. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993; 21: 1134-1141. (Pubitemid 23348354)
37. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54: 257-268. (Pubitemid 23294526)
38. Aman MG, Vinks AA, Remmerie B, Mannaert E, Ramadan Y, Masty J et al. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther 2007; 29: 1476-1486. (Pubitemid 47348123)
39. Zhou ZL, Li X, Peng HY, Yu XY, Yang M, Su FL et al. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol Sin 2006; 27: 381-386. (Pubitemid 43357037)
40. van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther 2003; 25: 1687-1699. (Pubitemid 36801942)
41. King DJ. Guidelines for the use of antipsychotic drug studies in healthy volunteers. The BAP Consensus Group. J Psychopharmacol 1997; 11: 201-209. (Pubitemid 27375875)
42. Barrett SL, Bell R, Watson D, King DJ. Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers. J Psychopharmacol 2004; 18: 156-172. (Pubitemid 38954902)
43. Domino EF, Zsigmond EK, Domino LE, Domino KE, Kothary SP, Domino SE. Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay. Anesth Analg 1982; 61: 87-92. (Pubitemid 12184628)
44. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 1998; 11: 125-136. (Pubitemid 28097797)
45. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812.
46. Ventura MA, Green MF, Shaner A, Liberman RP. Training and quality assurance with the brief psychiatric rating scale:'The drift buster'. Int J Methods Psychiatric Res 1993; 3: 221-244.
47. Launay G, Slade P. The measurement of hallucinatory predisposition in male and female prisoners. Personality and Individual Differences 1981; 2(3): 221-234.
48. Lees J, Hallak JE, Deakin JF, Dursun SM. Gender differences and the effects of ketamine in healthy volunteers. J Psychopharmacol 2004; 18: 337-339. (Pubitemid 39382561)
49. Field A. Discovering Statistics Using SPSS 2nd. Sage Publications Inc. 2005.
50. Lencer R, Trillenberg P. Neurophysiology and neuroanatomy of smooth pursuit in humans. Brain Cogn 2008; 68: 219-228.
51. Andreasen NC, Paradiso S, O'Leary DS. 'Cognitive dysmetria' as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical- cerebellar circuitry? Schizophr Bull 1998; 24: 203-218. (Pubitemid 28404981)
52. Crawford TJ, Sharma T, Puri BK, Murray RM, Berridge DM, Lewis SW. Saccadic eye movements in families multiply affected with schizophrenia: the Maudsley Family Study. Am J Psychiatry 1998; 155: 1703-1710.
53. Aasen I, Kolli L, Kumari V. Sex effects in prepulse inhibition and facilitation of the acoustic startle response: implications for pharmacological and treatment studies. J Psychopharmacol 2005; 19: 39-45.
54. Kumari V, Aasen I, Sharma T. Sex differences in prepulse inhibition deficits in chronic schizophrenia. Schizophr Res 2004; 69: 219-235. (Pubitemid 38721421)
55. Morgan CJ, Perry EB, Cho HS, Krystal JH, D'Souza DC. Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology (Berl) 2006; 187: 405-414. (Pubitemid 44200512)
56. Riecher-Rossler A. Oestrogen effects in schizophrenia and their potential therapeutic implications-review. Arch Womens Ment Health 2002; 5: 111-118. (Pubitemid 35387789)
57. Breese GR, Knapp DJ, Moy SS. Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neurosci Biobehav Rev 2002; 26: 441-455. (Pubitemid 36158662)
58. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 1999; 145: 193-204. (Pubitemid 29362018)
59. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57(3): 270-276. (Pubitemid 30140436)
60. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005; 179: 303-309. (Pubitemid 40576718)
61. Hutton SB, Crawford TJ, Gibbins H, Cuthbert I, Barnes TR, Kennard C et al. Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia. Psychopharmacology (Berl) 2001; 157: 284-291. (Pubitemid 32905570)
62. Lencer R, Sprenger A, Harris MS, Reilly JL, Keshavan MS, Sweeney JA. Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia. Arch Gen Psychiatry 2008; 65: 1146-1154.
63. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 2008; 65: 154-164. (Pubitemid 351214314)
64. Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T et al. NMDA receptors, cognition and schizophrenia-testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 2012; 62: 1401-1412.
65. De Simoni S, Schwarz AJ, O'Daly OG, Marquand AF, Brittain C, Gonzales C et al. Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage 2013; 64: 75-90.
66. Javitt DC. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci 2010; 47: 4-16.
67. Gooding DC, Basso MA. The tell-tale tasks: a review of saccadic research in psychiatric patient populations. Brain Cogn 2008; 68: 371-390.
68. Allman AA, Benkelfat C, Durand F, Sibon I, Dagher A, Leyton M et al. Effect of D-amphetamine on inhibition and motor planning as a function of baseline performance. Psychopharmacology (Berl) 2010; 211: 423-433.
69. Babin SL, Hood AJ, Wassef AA, Williams NG, Patel SS, Sereno AB. Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1753-1764.
70. Green JF, King DJ, Trimble KM. Antisaccade and smooth pursuit eye movements in healthy subjects receiving sertraline and lorazepam. J Psychopharmacol 2000; 14: 30-36. (Pubitemid 30156535)
71. Honey GD, O'Loughlin C, Turner DC, Pomarol-Clotet E, Corlett PR, Fletcher PC. The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia. Neuropsychopharmacology 2006; 31: 413-423. (Pubitemid 43113405)
72. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn (DSM-IV). American Psychiatric Association: Washington DC, USA, 1994. 73
73. World Health Organization. ICD-10. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization: Geneva, Switzerland, 1992.
74. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl 20): 22-33, quiz 34-57: 22-33. (Pubitemid 29001829)
75. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100 (Pubitemid 17115352)
76. Reilly JL, Lencer R, Bishop JR, Keedy S, Sweeney JA. Pharmacological treatment effects on eye movement control. Brain Cogn 2008; 68: 415-435.
77. de Visser SJ, van der Post J, Pieters MS, Cohen AF, van Gerven JM. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 2001; 51: 119-132. (Pubitemid 32219735)
78. Ettinger U, Picchioni M, Hall MH, Schulze K, Toulopoulou T, Landau S et al. Antisaccade performance in monozygotic twins discordant for schizophrenia: the Maudsley twin study. American Journal of Psychiatry 2006; 163: 543-545. (Pubitemid 44469403)
79. Hutton SB, Ettinger U. The antisaccade task as a research tool in psychopathology: a critical review. Psychophysiology 2006; 43: 302-213.
80. Levy DL, Sereno AB, Gooding DC, O'Driscoll GA. Eye tracking dysfunction in schizophrenia: characterization and pathophysiology. Curr Top Behav Neurosci 2010; 4: 311-347.
81. Smyrnis N, Evdokimidis I, Mantas A, Kattoulas E, Stefanis NC, Constantinidis TS et al. Smooth pursuit eye movements in 1,087 men: effects of schizotypy, anxiety, and depression. Exp Brain Res 2007; 179: 397-408. (Pubitemid 46716593)
82. Smyrnis N, Evdokimidis I, Stefanis NC, Avramopoulos D, Constantinidis TS, Stavropoulos A et al. Antisaccade performance of 1,273 men: effects of schizotypy, anxiety, and depression. J Abnorm Psychol 2003; 112: 403-414. (Pubitemid 36959366)
83. Hutton SB. Cognitive control of saccadic eye movements. Brain Cogn 2008; 68: 327-340.
84. Barnes GR. Cognitive processes involved in smooth pursuit eye movements. Brain Cogn 2008; 68: 309-326.
85. Sharpe JA. Neurophysiology and neuroanatomy of smooth pursuit: lesion studies. Brain Cogn 2008; 68: 241-254.
86. Avila MT, Weiler MA, Lahti AC, Tamminga CA, Thaker GK. Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am J Psychiatry 2002; 159: 1490-1496. (Pubitemid 35006728)
87. Condy C, Wattiez N, Rivaud-Pechoux S, Gaymard B. Ketamine-induced distractibility: An oculomotor study in monkeys. Biol Psychiatry 2005; 57: 366-372. (Pubitemid 40215766)
88. Radant AD, Bowdle TA, Cowley DS, Kharasch ED, Roy-Byrne PP. Does ketaminemediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 1998; 19: 434-444. (Pubitemid 28451599)
89. Weiler MA, Thaker GK, Lahti AC, Tamminga CA. Ketamine effects on eye movements. Neuropsychopharmacology 2000; 23: 645-653.
90. Morgan CJ, Huddy V, Lipton M, Curran HV, Joyce EM. Is persistent ketamine use a valid model of the cognitive and oculomotor deficits in schizophrenia? Biol Psychiatry 2009; 65: 1099-1102.
91. Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 2011; 213: 289-305.
92. Large CH. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol 2007; 21: 283-301. (Pubitemid 46934046)
93. Doyle OM, De Simoni S, Schwarz AJ, Brittain C, O'Daly OG, Williams SC et al. Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents. J Pharmacol Exp Ther 2013; 345: 151-160.
94. Burke JG, Reveley MA. Improved antisaccade performance with risperidone in schizophrenia. J Neurol Neurosurg Psychiatry 2002; 72: 449-454.
95. Harris MS, Reilly JL, Keshavan MS, Sweeney JA. Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia. Psychol Med 2006; 36: 485-494. (Pubitemid 43381001)
96. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 1991; 17: 555-564.
97. O'Driscoll GA, Lenzenweger MF, Holzman PS. Antisaccades and smooth pursuit eye tracking and schizotypy. Arch Gen Psychiatry 1998; 55: 837-843. (Pubitemid 28413047)
98. Ettinger U, Kumari V, Crawford TJ, Flak V, Sharma T, Davis RE et al. Saccadic eye movements, schizotypy, and the role of neuroticism. Biol Psychol 2005; 68: 61-78. (Pubitemid 39092932)
99. Schmechtig A, Lees J, Grayson L, Craig KJ, Dadhiwala R, Dawson GR et al. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. Psychopharmacology (Berl) 2013; 227: 331-345.
100. Nelson HE. The National Adult Reading Test (NART). NFER-Nelson: Windsor UK, 1982.
101. Ettinger U, Kumari V, Zachariah E, Galea A, Crawford TJ, Corr PJ et al. Effects of procyclidine on eye movements in schizophrenia. Neuropsychopharmacology 2003; 28: 2199-2208. (Pubitemid 37468188)
102. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993; 21: 1134-1141. (Pubitemid 23348354)
103. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54: 257-268. (Pubitemid 23294526)
104. Aman MG, Vinks AA, Remmerie B, Mannaert E, Ramadan Y, Masty J et al. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther 2007; 29: 1476-1486. (Pubitemid 47348123)
105. Zhou ZL, Li X, Peng HY, Yu XY, Yang M, Su FL et al. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol Sin 2006; 27: 381-386. (Pubitemid 43357037)
106. van Schaick EA, Lechat P, Remmerie BM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther 2003; 25: 1687-1699. (Pubitemid 36801942)
107. King DJ. Guidelines for the use of antipsychotic drug studies in healthy volunteers. The BAP Consensus Group. J Psychopharmacol 1997; 11: 201-209. (Pubitemid 27375875)
108. Barrett SL, Bell R, Watson D, King DJ. Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers. J Psychopharmacol 2004; 18: 156-172. (Pubitemid 38954902)
109. Domino EF, Zsigmond EK, Domino LE, Domino KE, Kothary SP, Domino SE. Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay. Anesth Analg 1982; 61: 87-92. (Pubitemid 12184628)
110. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 1998; 11: 125-136. (Pubitemid 28097797)
111. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812.
112. Ventura MA, Green MF, Shaner A, Liberman RP. Training and quality assurance with the brief psychiatric rating scale: 'The drift buster'. Int J Methods Psychiatric Res 1993; 3: 221-244.
113. Launay G, Slade P. The measurement of hallucinatory predisposition in male and female prisoners. Personality and Individual Differences 1981; 2(3): 221-234.
114. Lees J, Hallak JE, Deakin JF, Dursun SM. Gender differences and the effects of ketamine in healthy volunteers. J Psychopharmacol 2004; 18: 337-339. (Pubitemid 39382561)
115. Field A. Discovering Statistics Using SPSS, vol. 2nd. Sage Publications Inc, 2005.
116. Lencer R, Trillenberg P. Neurophysiology and neuroanatomy of smooth pursuit in humans. Brain Cogn 2008; 68: 219-228.
117. Andreasen NC, Paradiso S, O'Leary DS. 'Cognitive dysmetria' as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical- cerebellar circuitry? Schizophr Bull 1998; 24: 203-218. (Pubitemid 28404981)
118. Crawford TJ, Sharma T, Puri BK, Murray RM, Berridge DM, Lewis SW. Saccadic eye movements in families multiply affected with schizophrenia: the Maudsley Family Study. Am J Psychiatry 1998; 155: 1703-1710.
119. Aasen I, Kolli L, Kumari V. Sex effects in prepulse inhibition and facilitation of the acoustic startle response: implications for pharmacological and treatment studies. J Psychopharmacol 2005; 19: 39-45.
120. Kumari V, Aasen I, Sharma T. Sex differences in prepulse inhibition deficits in chronic schizophrenia. Schizophr Res 2004; 69: 219-235. (Pubitemid 38721421)
121. Morgan CJ, Perry EB, Cho HS, Krystal JH, D'Souza DC. Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology (Berl) 2006; 187: 405-414. (Pubitemid 44200512)
122. Riecher-Rossler A. Oestrogen effects in schizophrenia and their potential therapeutic implications-review. Arch Womens Ment Health 2002; 5: 111-118. (Pubitemid 35387789)
123. Breese GR, Knapp DJ, Moy SS. Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neurosci Biobehav Rev 2002; 26: 441-455. (Pubitemid 36158662)
124. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 1999; 145: 193-204. (Pubitemid 29362018)
125. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57(3): 270-276. (Pubitemid 30140436)
126. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005; 179: 303-309. (Pubitemid 40576718)
127. Hutton SB, Crawford TJ, Gibbins H, Cuthbert I, Barnes TR, Kennard C et al. Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia. Psychopharmacology (Berl) 2001; 157: 284-291. (Pubitemid 32905570)
128. Lencer R, Sprenger A, Harris MS, Reilly JL, Keshavan MS, Sweeney JA. Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia. Arch Gen Psychiatry 2008; 65: 1146-1154.
129. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 2008; 65: 154-164. (Pubitemid 351214314)
130. Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T et al. NMDA receptors, cognition and schizophrenia-testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 2012; 62: 1401-1412.
131. De Simoni S, Schwarz AJ, O'Daly OG, Marquand AF, Brittain C, Gonzales C et al. Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage 2013; 64: 75-90.
132. Javitt DC. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci 2010; 47: 4-16.
133. Gooding DC, Basso MA. The tell-tale tasks: a review of saccadic research in psychiatric patient populations. Brain Cogn 2008; 68: 371-390.
134. Allman AA, Benkelfat C, Durand F, Sibon I, Dagher A, Leyton M et al. Effect of D-amphetamine on inhibition and motor planning as a function of baseline performance. Psychopharmacology (Berl) 2010; 211: 423-433.
135. Babin SL, Hood AJ, Wassef AA, Williams NG, Patel SS, Sereno AB. Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1753-1764.
136. Green JF, King DJ, Trimble KM. Antisaccade and smooth pursuit eye movements in healthy subjects receiving sertraline and lorazepam. J Psychopharmacol 2000; 14: 30-36. (Pubitemid 30156535)
137. Honey GD, O'Loughlin C, Turner DC, Pomarol-Clotet E, Corlett PR, Fletcher PC. The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia. Neuropsychopharmacology 2006; 31: 413-423. (Pubitemid 43113405)
138. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn (DSM-IV). American Psychiatric Association: Washington DC, USA, 1994.
139. World Health Organization. ICD-10. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization: Geneva, Switzerland, 1992.
140. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl 20): 22-33, quiz 34-57: 22-33. (Pubitemid 29001829)
141. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100. (Pubitemid 17115352)